Suppr超能文献

静脉用质子泵抑制剂在非 ICU 患者中的临床和成本影响。

Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients.

机构信息

Department of Pharmacy Practice, School of Pharmacy, Lebanese American University, Byblos Campus, PO Box 36, 13-5053 Beirut, Lebanon.

出版信息

World J Gastroenterol. 2010 Feb 28;16(8):982-6. doi: 10.3748/wjg.v16.i8.982.

Abstract

AIM

To assess the appropriateness of the indication and route of administration of proton-pump-inhibitors (PPIs) and their associated cost impact.

METHODS

Data collection was performed prospectively during a 6-mo period on 340 patients who received omeprazole intravenously during their hospital stay in non-intensive care floors. Updated guidelines were used to assess the appropriateness of the indication and route of administration.

RESULTS

Complete data collection was available for 286 patients which were used to assess intravenous (IV) PPIs utilization. Around 88% of patients were receiving PPIs for claimed stress ulcer prophylaxis (SUP) indication; of which, only 17% met the guideline criteria for SUP indication, 14% met the criteria for non-steroidal-anti-inflammatory drugs-induced ulcer prophylaxis, while the remaining 69% were identified as having an unjustified indication for PPI use. The initiation of IV PPIs was appropriate in 55% of patients. Half of these patients were candidates for switching to the oral dosage form during their hospitalization, while only 36.7% of these patients were actually switched. The inappropriate initiation of PPIs via the IV route was more likely to take place on the medical floor than the surgical floor (53% vs 36%, P = 0.003). The cost analysis associated with the appropriateness of the indication for PPI use as well as the route of administration of PPI revealed a possible saving of up to $17,732.5 and $14,571, respectively.

CONCLUSION

This study highlights the over-utilization of IV PPIs in non-intensive care unit patients. Restriction of IV PPI use for justified indications and route of administration is recommended.

摘要

目的

评估质子泵抑制剂(PPIs)的适应证和给药途径的适宜性及其相关成本影响。

方法

在非重症监护病房住院期间接受静脉注射奥美拉唑的 340 例患者中,前瞻性地进行了为期 6 个月的数据收集。使用更新的指南评估适应证和给药途径的适宜性。

结果

286 例患者可用于评估静脉(IV)PPI 的使用情况,可完整收集数据。约 88%的患者因声称的应激性溃疡预防(SUP)适应证接受 PPI 治疗;其中,仅 17%符合 SUP 适应证指南标准,14%符合非甾体抗炎药诱导性溃疡预防标准,而其余 69%被认为是 PPI 使用无正当适应证。IV PPI 的起始治疗在 55%的患者中是适宜的。这些患者中有一半在住院期间有转换为口服剂型的适应证,而实际上只有 36.7%的患者进行了转换。不合理地通过 IV 途径起始 PPI 更可能发生在内科病房而不是外科病房(53%比 36%,P = 0.003)。与 PPI 适应证适宜性以及 PPI 给药途径相关的成本分析显示,可能最多可节省 17732.5 美元和 14571 美元。

结论

本研究强调了非重症监护病房患者中 IV PPI 的过度使用。建议限制 IV PPI 仅用于有合理适应证和给药途径的情况。

相似文献

1
Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients.
World J Gastroenterol. 2010 Feb 28;16(8):982-6. doi: 10.3748/wjg.v16.i8.982.
2
Pattern of intravenous proton pump inhibitors use in ICU and Non-ICU setting: a prospective observational study.
Saudi J Gastroenterol. 2010 Oct-Dec;16(4):275-9. doi: 10.4103/1319-3767.70614.
5
Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of current practice in a general surgery department.
J Eval Clin Pract. 2013 Apr;19(2):374-8. doi: 10.1111/j.1365-2753.2012.01838.x. Epub 2012 Mar 15.
6
Evaluation of Proton Pump Inhibitors Prescribing Among Hospitalized Patients: A Cross-Sectional Study.
Int J Gen Med. 2023 Jan 11;16:141-150. doi: 10.2147/IJGM.S396202. eCollection 2023.
8
Use of intravenous proton-pump inhibitors in a teaching hospital practice.
Dig Dis Sci. 2009 Sep;54(9):1947-52. doi: 10.1007/s10620-008-0568-4. Epub 2008 Nov 26.
9
The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients.
Int J Clin Pharm. 2015 Dec;37(6):1152-61. doi: 10.1007/s11096-015-0178-0. Epub 2015 Aug 30.
10
The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage.
Clin Gastroenterol Hepatol. 2006 Aug;4(8):988-997. doi: 10.1016/j.cgh.2006.05.019. Epub 2006 Jul 17.

引用本文的文献

1
Insights into stress ulcer prophylaxis among non-critically ill patients: a tertiary hospital perspective from Sudan.
J Pharm Health Care Sci. 2025 Aug 11;11(1):71. doi: 10.1186/s40780-025-00483-w.
5
Appropriateness and inappropriate medication predictors of stress ulcer prophylaxis in the intensive care unit.
Front Pharmacol. 2025 Jan 7;15:1401335. doi: 10.3389/fphar.2024.1401335. eCollection 2024.
8
Evaluation of Proton Pump Inhibitors Prescribing Among Hospitalized Patients: A Cross-Sectional Study.
Int J Gen Med. 2023 Jan 11;16:141-150. doi: 10.2147/IJGM.S396202. eCollection 2023.
10
A Cross-Sectional Study on Single-Day Use of Proton Pump Inhibitors in Tertiary Care Hospitals of South India.
Hosp Pharm. 2021 Apr;56(2):109-115. doi: 10.1177/0018578719873876. Epub 2019 Sep 10.

本文引用的文献

2
Proton pump inhibitors: actions and reactions.
Drug Discov Today. 2009 Jul;14(13-14):647-60. doi: 10.1016/j.drudis.2009.03.014. Epub 2009 Apr 8.
3
Appropriate proton pump inhibitor use among older adults: a retrospective chart review.
Am J Geriatr Pharmacother. 2008 Dec;6(5):249-54. doi: 10.1016/j.amjopharm.2008.12.001.
4
Use of intravenous proton-pump inhibitors in a teaching hospital practice.
Dig Dis Sci. 2009 Sep;54(9):1947-52. doi: 10.1007/s10620-008-0568-4. Epub 2008 Nov 26.
6
Stress ulcer prophylaxis in hospitalized patients not in intensive care units.
Am J Health Syst Pharm. 2007 Jul 1;64(13):1396-400. doi: 10.2146/ajhp060393.
7
Intravenous proton pump inhibitor use in hospital practice.
Eur J Gastroenterol Hepatol. 2007 Jun;19(6):461-4. doi: 10.1097/MEG.0b013e32810fd88a.
8
Predictors of inappropriate utilization of intravenous proton pump inhibitors.
Aliment Pharmacol Ther. 2007 Mar 1;25(5):609-15. doi: 10.1111/j.1365-2036.2006.03226.x.
10
Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.
Nat Clin Pract Gastroenterol Hepatol. 2006 Oct;3(10):563-73. doi: 10.1038/ncpgasthep0610.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验